2008 a Record Year for Gerresheimer

Dusseldorf (ots) -

- Strong focus on the markets of pharma & life science

- Annual General Meeting passes dividend of EUR 0.40 per share

The Annual General Meeting of Gerresheimer AG today passed an
unchanged dividend of EUR 0.40 per share following the record year in
2008.

The Company finished the financial year 2008 with record results.
Gerresheimer achieved sales of EUR.06 billion (prior year EUR 957.7m)
and operating results (adjusted EBITDA) of EUR 06.4m (prior year EUR
181.6m).

At the Annual General Meeting in Düsseldorf the CEO Dr. Axel
Herberg summarized the highlights of the financial year 2008: "We
have achieved record levels in terms of sales and earnings.
Gerresheimer is on a good course and will show itself to be very
robust even in times of crisis.?

The shareholders approved the actions of the members of the
Company?s Supervisory Board and Management Board for the financial
year 2008 and, as in the prior year, passed a dividend payment of EUR
0.40 per share.

With share capital representation of 59.44% the Annual General
Meeting passed the following resolutions:

ITEM 2: Appropriation of net earnings for the financial year
2008:
(99.99% of votes in favor)

ITEM 3: Approval of the actions of the Management Board members
for the financial year 2008:
(100% of votes in favor)

ITEM 4: Approval of the actions of the Supervisory Board members
for the financial year 2008:
(100% of votes in favor)

ITEM 5: Supplementary election to the Supervisory Board of Mr.
Theodor Stuth, Auditor and Certified Tax Advisor, Neuss:
(100% of votes in favor)

ITEM 6: Election of the auditor for the financial year
2009:
(99.99% of votes in favor)

The speech is available on www.gerresheimer.com/en/press.html .

About Gerresheimer

Gerresheimer employs around 10,000 people in 42 locations in
Europe, America and Asia. In the financial year 2008, worldwide sales
totalled ?1.06bn. The product portfolio ranges from pharma¬ceu¬tical
vials made of glass and plastic through to complex drug-delivery
systems for the pharma & life science industry. These include sterile
syringes, inhalers and other system-based approaches for safe dosage
and application of medications. The Group enjoys a leading position
in markets which are characterised by high technical and regulatory
barriers.

Originaltext: Gerresheimer AG
digital press kits: http://www.presseportal.de/pm/9072
press kits via RSS: http://www.presseportal.de/rss/pm_9072.rss2
ISIN: DE000A0LD6E6

Pressekontakt:
Contact Press
Burkhard Lingenberg
Director Corporate Communication & Marketing
Phone +49 211 6181-250
Fax +49 211 6181-241
e-mail b.lingenberg@gerresheimer.com

Contact Investor Relations
Anke Linnartz
Director Corporate Investor Relations
Phone +49 211 6181-314
Fax +49 211 6181-121
e-mail a.linnartz@gerresheimer.com